Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.220
+0.010 (0.83%)
At close: Sep 18, 2025, 4:00 PM EDT
1.180
-0.040 (-3.28%)
After-hours: Sep 18, 2025, 5:40 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending May 31, 2025, with 107.14% growth. This brings the company's revenue in the last twelve months to $615.92K, up 49.85% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$615.92K
Revenue Growth
+49.85%
P/S Ratio
33.46
Revenue / Employee
$87,989
Employees
7
Market Cap
23.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LEXX News
- 22 days ago - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference - TheNewswire
- 5 weeks ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - Accesswire
- 6 weeks ago - GLP-1 "Arms Race" Broadens to Include Dozens of Companies - Accesswire
- 7 weeks ago - Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study - TheNewswire
- 7 weeks ago - Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study - Accesswire
- 2 months ago - Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry - Accesswire
- 3 months ago - Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide - TheNewswire
- 3 months ago - Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TheNewswire